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Summary
Background The use of a combination of the integrase inhibitor, cabotegravir, and the non-nucleoside reverse 
transcriptase inhibitor, rilpivirine, in a long-acting injectable form is being considered as an antiretroviral treatment 
option for people with HIV in sub-Saharan Africa. We aimed to model the effects of injectable cabotegravir–rilpivirine 
to help to inform its potential effectiveness and cost-effectiveness under different possible policies for its introduction.
Methods We used an existing individual-based model of HIV to predict the effects of introducing monthly injections 
of cabotegravir–rilpivirine for people with HIV in low-income settings in sub-Saharan Africa. We evaluated policies in 
the context of 1000 setting scenarios that reflected characteristics of HIV epidemics and programmes in sub-Saharan 
Africa. We compared three policies for introduction of injectable cabotegravir–rilpivirine with continued use of 
dolutegravir-based oral regimens for: all individuals on antiretroviral therapy (ART); individuals with a recently 
measured viral load of more than 1000 copies per mL (signifying poor adherence to oral drugs, and often associated 
with drug resistance); and individuals with a recently measured viral load of less than 1000 copies per mL (a group 
with a lower prevalence of pre-existing drug resistance). We also did cost-effectiveness analysis, taking a health system 
perspective over a 10 year period, with 3% discounting of disability-adjusted life-years (DALYs) and costs. A cost-
effectiveness threshold of US$500 per DALY averted was used to establish if a policy was cost-effective. 
Findings In our model, all policies involving the introduction of injectable cabotegravir–rilpivirine were predicted to lead 
to an increased proportion of people with HIV on ART, increased viral load suppression, and decreased AIDS-related 
mortality, with lesser benefits in people with a recently measured viral load of less than 1000 copies per mL. Its 
introduction is also predicted to lead to increases in resistance to integrase inhibitors and non-nucleoside reverse 
transcriptase inhibitors if introduced in all people with HIV on ART or in those with a recently measured viral load of 
less than 1000 copies per mL, but to a lesser extent if introduced in people with more than 1000 copies per mL due to 
concentration of its use in people less adherent to oral therapy. Consistent with the effect on AIDS-related mortality, all 
approaches to the introduction of injectable cabotegravir–rilpivirine are predicted to avert DALYs. Assuming a cost 
of $120 per person per year, use of this regimen in people with a recently measured viral load of more than 1000 copies 
per mL was borderline cost-effective (median cost per DALY averted across setting scenarios $404). The other approaches 
considered for its use are unlikely to be cost-effective unless the cost per year of injectable cabotegravir–rilpivirine is 
considerably reduced.
Interpretation Our modelling suggests that injectable cabotegravir–rilpivirine offers potential benefits; however, to be 
a cost-effective option, its introduction might need to be carefully targeted to individuals with HIV who might otherwise 
have suboptimal adherence to ART. As data accumulate from trials and implementation studies, such findings can be 
incorporated into the model to better inform on the full consequences of policy alternatives.
Funding Bill & Melinda Gates Foundation, including through the HIV Modelling Consortium (OPP1191655).
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Until 2020, antiretroviral drug regimens in sub-Saharan 
Africa consisted of two nucleoside reverse transcriptase 
inhibitors (most commonly lamivudine and tenofovir 
disoproxil fumarate) and a non-nucleoside reverse 
transcriptase inhibitor (most commonly efavirenz). Due 
to concerns over increasing transmission of resistance to 
non-nucleoside reverse transcriptase inhibitors, in 2019, 
WHO strongly recommended a change in regimen for 
people initiating first-line antiretroviral therapy (ART) to 
the integrase inhibitor, dolutegravir, with lamivudine and 
tenofovir disoproxil fumarate.1 To date, only oral drug 
regimens have been available.
A combination of the integrase strand transfer inhibitor, 
cabotegravir, and the non-nucleoside reverse transcriptase 
inhibitor, rilpivirine, is likely to become available as ART 
in long-acting injectable form, with one or two monthly 
intramuscular injections.2–4 There is interest in the 
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possibility of injectable cabotegravir–rilpivirine use in 
sub-Saharan Africa.5 Potential advantages of injectable 
forms over current oral regimens are that injections result 
in adequate drug concentrations for a 1–2 month period, 
without dependence on adherence to daily oral pill taking. 
Disadvantages include cabotegravir appearing to have a 
lower barrier to resistance than does dolutegravir;6 a long 
so-called tail of cabotegravir drug concentrations if 
combination treatment is stopped, which might lead to 
selection of drug resistance if other antiretroviral drugs are 
not taken, potentially risking class-wide integrase strand 
transfer inhibitor resistance;7 injections might be painful 
and induce injection-site skin reactions; and the possibility 
of higher costs with injectables forms than with oral 
therapy for procurement and delivery, as well as a 
greater time commitment for clinic staff. Studies of 
implementation of injectable cabotegravir–rilpivirine in 
low-income settings in sub-Saharan Africa might be 
guided usefully by modelling exercises exploring potential 
effects in different subpopulations. We aimed to model the 
effects of injectable cabotegravir–rilpivirine on ART 
outcomes in patients with HIV from these settings and to 
assess its cost-effectiveness to help to inform potential 
policies for its introduction.
Methods 
Modelling approach 
The HIV synthesis model is an individual-based 
simulation model that has been described in detail 
elsewhere.8,9 Each time the model programme is run, it 
creates a simulated dataset of attributes of a population 
of adults from 1989 (the notional start date of the HIV 
epidemic), with updates every month (adapted from 
3 months for this exercise) on variables including age, 
sex, presence of a primary condomless sex partner 
and number of short-term condomless sex partners, 
HIV testing, male circumcision, use of pre-exposure 
prophylaxis and, for HIV-positive people, time from 
infection, CD4 cell count, viral load, specific antiretroviral 
drugs being used, antiretroviral drug adherence (for oral 
drugs), and specific drug resistance mutations. In this 
analysis, adherence refers to the extent of optimal pill 
taking as prescribed in the 1 month period among people 
who are attending clinic. ART interruption is modelled 
separately. Adherence to the specific drugs being taken 
and the presence of drug resistance mutations jointly 
determine the current amounts of suppressive antiviral 
effect of the regimen at any point in time. Through 
sampling of several parameter values, we create a series 
of so-called setting scenarios reflecting uncertainty in 
assumptions and a range of characteristics similar to 
those seen in southern and east Africa. For example, we 
sample parameters relating to rates of HIV testing; 
linkage and retention; adherence to oral antiretroviral 
drugs; resistance emer gence, transmission, and persis-
tence; ART interruption; extent of implementation of 
viral load monitoring; and rate of switching to second-
line therapy after detected virological failure. A table of 
parameters and the criteria for a setting scenario to be 
accepted are provided in the appendix (pp 2–10). With 
our setting scenarios, we aim to reflect subsettings 
within countries, not just countries in aggregate.
For each setting scenario, we randomly sampled 
injectable cabotegravir–rilpivirine introduction policies, 
modelling transition to injectable cabotegravir–rilpivirine 
for three groups: first, all people on ART; second, people 
with a most recently measured viral load of more than 
1000 copies per mL (as a means of selecting people with 
a tendency for poorer adherence to oral drugs); and third, 
people with a recently measured viral load of less than 
1000 copies per mL (a group with a lower prevalence of 
pre-existing drug resistance).
Research in context
Evidence before this study
The use of a combination of the integrase inhibitor, cabotegravir, 
and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, 
in long-acting injectable form as an antiretroviral treatment 
option in sub-Saharan Africa is being considered. Modelling can 
help to inform potential policies for its introduction. We searched 
Web of Science, with no restrictions on language, using the 
search terms “cabotegravir” AND (list of countries in sub-Saharan 
Africa) on June 30, 2020, and identified one modelling study that 
has considered the cost-effectiveness of the introduction of such 
treatment in adolescents in the context of Kenya, and found that 
this could be cost-effective if associated with an additional 
annual cost of US$89 or less.
Added value of this study
We used an existing individual-based model of HIV to consider 
the predicted effects and cost-effectiveness of the 
introduction of monthly injectable cabotegravir–rilpivirine. 
We considered drug resistance to cabotegravir and rilpivirine, 
cross resistance with oral drugs of the same classes, and the 
long tail of cabotegravir drug concentrations in people who 
stop attending for monthly injections.
Implications of all the available evidence
Injectable cabotegravir–rilpivirine offers potential benefits; 
however, its introduction needs to be carefully targeted to 
individuals who might otherwise have suboptimal adherence 
to ART and studied in pilot implementation projects to 
ascertain if it is likely to be a cost-effective option. 
See Online for appendix
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Context 
We assumed a context where dolutegravir was introduced 
over 2019–20 and where all people on ART were switched 
to tenofovir disoproxil fumarate–lamivudine–dolutegravir. 
If there were two viral load values above 1000 copies 
per mL on this regimen, it was switched to boosted 
protease inhibitor plus zidovudine and lamivudine. We 
further assumed that viral load monitoring was in place, 
but with varying levels of implementation across setting 
scenarios. 
Cost-effectiveness analysis 
Outcomes compared include the proportion of people 
on ART with viral suppression, AIDS-related deaths, 
disability-adjusted life-years (DALYs), and net DALYs 
(which account for costs of a policy on the basis of a cost-
effectiveness threshold of US$500 per DALY averted). The 
cost-effectiveness threshold should reflect the health gains 
that could have been delivered through other interven-
tions that can no longer be provided if the evaluated 
interventions are funded (ie, the health opportunity 
costs).10 HIV care in sub-Saharan Africa is mainly funded 
by external development assistance; therefore, this is 
unlikely to depend as much on a country’s income level 
for HIV spending as for general health care. Although 
uncertain, $500 averted per DALY is likely to be at the 
upper end for lower-income countries in the region, on 
the basis of evidence concerning how resources could 
otherwise be used. Incremental cost-effectiveness ratios 
for funded interventions such as the expansion of ART to 
every patient with diagnosed HIV, which includes an 
increased need for testing and use of viral load monitoring, 
are around this value.11,12 Given the discussions around 
feasibility of implementation at the time of adoption, 
these appear to be on the borderline of cost-effective 
interventions. Furthermore, for South Africa, a middle-
income country that funds most of its programme 
through domestic funding, a cost-effectiveness threshold 
of $750 has been proposed because this is approximately 
the cost per life-year averted of HIV interventions at the 
borderline for inclusion within the South African HIV 
Investment Case, which prioritises use of the national 
HIV budget on the basis of intervention cost-
effectiveness.13
The cost of tenofovir disoproxil fumarate–lamivudine–
dolutegravir, including the supply chain, is assumed to 
be $78 per patient per year.14 The cost at which injectable 
cabotegravir–rilpivirine could be delivered is unknown 
and we initially use a cost of $120 per patient per year for 
illustrative purposes only, which includes all costs 
associated with its delivery, including that of the drug 
and supply chain, and any additional costs in the clinic 
beyond those required in the context of current oral drug 
use. Costs of providing clinic visits in the context of 
current oral drug use ($80 per patient per year unless 
viral load is known to be suppressed, in which case 
$40 per year; we make no explicit assumptions on 
prescription lengths for tenofovir disoproxil fumarate–
lamivudine–dolutegravir) and viral load testing 
($22 per test) are considered separately from these costs. 
Absolute numbers of health-related events, costs, and 
DALYs are relevant for a population with a size of 
approximately 10 million adults in 2020. The cost-
effectiveness analysis was done from a health-care 
perspective, with costs and health outcomes both 
discounted to present $ values at 3% per annum. Other 
unit costs and disability weights are described in the 
appendix (pp 11–12).
Modelling drug resistance
Before explaining how we modelled injectable 
cabotegravir–rilpivirine, we first describe how we 
modelled the effects of oral drug regimens. For an 
individual on oral ART in the model, the risk of new 
drug resistance mutations arising depends on their 
adherence in the current month, which is modelled as a 
percentage between 0% and 100% full adherence. People 
with an adherence of less than 80% in a given month 
have a substantially higher risk of drug resistance than 
those with an adherence of 80% or above. Risk of 
resistance mutations is drug-specific, but the relative 
rate of resistance between individuals with at least 
80% adherence and those with less than 80% adherence 
is assumed to be the same across drugs. These 
assumptions have been previously shown to lead to 
levels of drug resistance consistent with observed data.8,15 
People have a long-term average tendency to adhere to 
oral drugs, but there is variability within individuals by 
month.8 The current amount of activity of the overall 
regimen is the sum of the activity of each drug in the 
regimen, accounting for the intrinsic drug potency and 
the current level of resistance to the drug, in which the 
potency conveys the contribution of a drug to the 
antiviral activity of a regimen against a virus with no 
resistance, informed by early short-term studies of 
drugs in development used as monotherapy and inferred 
from the potency of regimens of drug combinations.8,15 
People can interrupt oral drugs and, if so, there is a 
high probability that this coincides with a stop in clinic 
attendance. In people with low long-term tendency 
to adhere to ART, there is an increased rate with 
which such interruption can occur. With the inclusion 
of long-acting injectable drugs, we generalised the 
adherence percentage to be thought of as a measure of 
the degree to which concentrations of the drugs being 
taken are optimal in the 1 month period. Where the 
percentage is above 80%, we referred to this as indicating 
optimal drug concentrations for the month; where it is 
below 80%, we referred to such as indicating suboptimal 
drug concentrations. We assumed that injections are 
monthly.
We modelled indicative non-nucleoside reverse 
transcriptase inhibitor mutations at reverse transcriptase 
codon positions 101, 103, 138, 181, 188, and 190. The risk 
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of resistance mutations with rilpivirine is higher than 
with efavirenz.16 We accounted for the fact that there is 
cross resistance between efavirenz and rilpivirine, 
although rilpivirine remains active in the presence of the 
Lys103Asn mutation. The risk of integrase mutations 
(Gln148 or Arg263 are the major integrase inhibitor 
mutations considered) is two times higher with 
cabotegravir than with dolutegravir. There is extensive 
cross resistance between cabotegravir and dolutegravir. 
The potency of each drug (the activity amount if no 
resistance mutations are present) is 1·0 for all nucleoside 
reverse transcriptase inhibitors. Efavirenz, rilpivirine, 
dolutegravir, and cabotegravir are assumed to have the 
same potency and this is set to 1·5 or 2·0 (determined by 
sampling for each run), and 2·0 for atazanavir and 
lopinavir.
Cabotegravir has a long half-life and, if no further 
injections or oral drugs are taken, the cabotegravir–
rilpivirine concentration after the most recent injection 
is assumed to remain above 80% of optimal drug 
concentration for 2 months (ie, at low-resistance risk) 
and then fall to a suboptimal concentration (ie, at high-
resistance risk) for the following 3, 6, or 12 months. The 
suboptimal concentration period of 3, 6, or 12 months is 
variable across individuals. During this period, there is 
some antiviral effect of the regimen. Thereafter, the drug 
concentration effectively falls to 0 and there is no residual 
antiviral effect or risk of resistance development.
Variations in the assumptions explored (with the 
percentage of setting scenarios reflecting our uncertainty) 
included a two times higher (33% of setting scenarios) or 
two times lower (33% of setting scenarios) rate of ART 
interruption with injectable cabotegravir–rilpivirine 
compared with oral antiretrovirals, rather than the two 
being the same (33% of setting scenarios). Additionally, 
people with lower adherence might tend to correspond to 
individuals with lower levels of sexual transmission risk 
(20% of setting scenarios). 
Role of the funding source 
The programme officers for the funder (GPG and PE) 
had input into the modelling design and are coauthors 
on this report as a result of their input and expertise. The 
funder of the study had no other role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
Table 1 shows the characteristics of the population in 
July, 2020, across 1000 setting scenarios, with observed 
values from sub-Saharan African countries provided for 
context, although we note that we aimed for our setting 
scenarios to also reflect the range of epidemic 
characteristics in specific subsettings within countries.
Table 2 shows the predicted effects of the introduction 
of injectable cabotegravir–rilpivirine for the three groups 
(ie, introduction targeted at all patients on ART, only at 
those with high viral loads, and only at those with low 
viral loads). If injectable cabotegravir–rilpivirine use 
was dependent on a recently measured viral load of more 
than 1000 copies per mL, patients would have a high 
prevalence of resistant virus when starting the regimen 
(table 2). All policies involving the introduction of 
injectable cabotegravir–rilpivirine were predicted to 
Sampled value Examples of observed data
HIV prevalence (aged 15–49 years), % 17% (5–33) Zimbabwe 2016 13%, Tanzania 2017 5%, Uganda 2017 6%, Lesotho 2017 24%, Eswatini 2017 27%, Malawi 2016 10%, 
Namibia 2017 12%, Zambia 2016 11%, Cameroon 2017 3·4%, Côte d’Ivoire 2017–18 2·5%
HIV incidence (aged 15–49 years), 
per 100 person-years
1·10 (0·25–2·87) Malawi 2016 0·37, Zambia 2016 0·66, Zimbabwe 2016 0·45, Lesotho 2017 1·55, Namibia 2016 0·40, Eswatini 2017 1·48, 
Tanzania 2017 0·27, Cameroon 2017 0·27
Proportion of HIV-positive people diagnosed, % 88% (69–95) Malawi 2016 77%, Zambia 2016 67%, Zimbabwe 2016 74%, Namibia 2017 86%, Tanzania 2017 52%, Ethiopia 2018 72%, 
Côte d’Ivoire 2017/18 37%, Cameroon 2017 47%
Proportion of diagnosed HIV-positive people 
on ART, %
88% (72–97) Lesotho 2016–17 92%, South Africa 2017 71%, Eswatini 2016–17 87%, Namibia 2017 96%, Zambia 2016 87%, Tanzania 
2016–17 94%, Ethiopia 2017–18 99%, Malawi 2016 91%, Uganda 2016–17 90%, Cameroon 2017 91%, Zimbabwe 2016 
87%, Côte d’Ivoire 2017–18 88%, Cameroon 2017 91%
Proportion of all HIV-positive people with a 
viral load of <1000 copies per mL, %
64% (44–80) Zambia 2016 60%, Malawi 2016 68%, Zimbabwe 2016 60%, Eswatini 2017 73%, Lesotho 2017 68%, Tanzania 2017 52%, 
Uganda 2017 60%, Namibia 2017 77%, Ethiopia 2018 70%, Côte d’Ivoire 2017–18 40%, Cameroon 2017 47%
Proportion of ART-experienced people who 
have started second-line ART, %
14% (6–35) Malawi approximately 3%*
Proportion of people on ART who have a viral 
load of <1000 copies per mL, %
90% (74–96) Zambia 2016 88% (men) and 90% (women), Malawi 2016 90% (men) and 92% (women), Zimbabwe 2016 84% (men) 
and 88% (women), Namibia 2017 92% (men) and 90% (women), Tanzania 2017 89% (men) and 83% (women), Ethiopia 
2018 95% (men) and 87% (women), Côte d’Ivoire 2017–18 76%, Cameroon 2017 80% 
Proportion of people on ART who have a CD4 
count of <500 cells per µL, % 
53% (49–60) Eswatini 2016–17 40%, Malawi 2016 52%, Tanzania 2017–18 55%, Zambia 2016 59%
Proportion of ART-naive people initiating ART 
who have non-nucleoside reverse transcriptase 
inhibitor resistance, %
13% (2–35) Angola 2012 14%, Botswana 2016 8%, South Africa 2017 14%, Zimbabwe 2015 10%, Namibia 9%, Uganda 2016 16%, 
Cameroon 8%†
Data are median (90% range), unless otherwise indicated. ART=antiretroviral therapy. *According to quarterly reports by Malawi’s Ministry of Health. †According to WHO’s HIV drug resistance report 2017.  
Table 1: Characteristics of HIV epidemics and programmes in 1000 setting scenarios at baseline (2020)
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lead to an increase in the proportion of people on ART 
who have viral load suppression and a decrease in 
AIDS-related deaths, compared with no introduction. Its 
introduction was also predicted to lead to increases 
in integrase inhibitor and non-nucleoside reverse 
transcriptase inhibitor resistance, if introduced in every 
patient on ART or in individuals with a recently measured 
viral load of less than 1000 copies per mL, but not in 
those with viral loads of more than 1000 copies per mL. 
This effect is due to the fact that use of injectable 
cabotegravir–rilpivirine is concentrated among people 
with reduced adherence to oral therapy, who would carry 
a risk of integrase inhibitor resistance with oral therapy. 
Consistent with the effect on AIDS-related mortality, all 
approaches to the introduction of injectable cabotegravir–
rilpivirine were predicted to avert DALYs.
With our assumed indicative cost of $120 per person 
per year for injectable cabotegravir–rilpivirine, overall 
programme costs were predicted to increase substantially 
with the policy for every patient on ART or for individuals 
with a viral load of less than 1000 copies per mL, but to a 
much lesser extent with the policy for those with a viral 
load of more than 1000 copies per mL (table 2). This 
difference is due to the targeting to people who are more 
costly to manage because of, for example, the high costs 
of second-line protease inhibitor-based regimens. Net 
DALYs are averted with the injectable cabotegravir–
rilpivirine policy for those with a viral load of more than 
Implementation in all people on ART  
(n=333 setting scenarios)
Implementation in people with a 
recently measured viral load of >1000 
copies per mL  
(n=334 setting scenarios)
Implementation in people with a 
recently measured viral load of <1000 
copies per mL  
(n=333 setting scenarios)
Percentage of people on ART on injectable CTG–RPV, % 99% (99 to 99; 97 to 100) 26% (25 to 27; 13 to 44) 86% (86 to 87; 75 to 94)
People starting injectable CTG–RPV
Percentage with viral load >1000 copies per mL*, % 40% (39 to 41; 26 to 56) 69% (68 to 71; 52 to 81) 4% (3 to 4; 1 to 7)
Percentage for whom first-line ART failed†, % 13% (0·12 to 0·13; 0·05 to 0·23) 25% (24 to 26; 13 to 38) 7% (6 to 7; 2 to 18)
Percentage with integrase inhibitor resistance, % 2% (2 to 2; 0 to 4) 7% (6 to 7; 2 to 13) 1% (0·01 to 0·02; 0·00 to 0·04)
Percentage with non-nucleoside reverse transcriptase 
inhibitor resistance, %
24% (23 to 26; 11 to 46) 38% (37 to 40; 18 to 59) 18% (17 to 20; 7 to 39)
Percentage male, % 40% (40 to 41; 34 to 48) 46% (45 to 47; 38 to 55) 39% (39 to 40; 33 to 46)
Percentage aged <25 years, % 5% (5 to 6; 1 to 12) 3% (3 to 4; 1 to 8) 5% (4 to 5; 1 to 10)
Introduction of injectable CTG–RPV vs no introduction
Difference in proportion of people with suboptimal drug 
concentrations (ie, <80% adherence to oral therapy) 
among people who started injectable cabotegravir–
rilpivirine, %
+8·0% (7·1 to 8·8; 0·0 to 19·5) +11·7% (10·3 to 2·6; 0·0 to 26·8) +7·4% (6·5 to 8·3; 1·2 to 18·0)
Difference in proportion of people with a viral load of 
<1000 copies per mL among people on ART, %
+5·3% (4·8 to 5·7; 1·0 to 14·4) +4·1% (3·7 to 4·4; 0·7 to 11·2) +3·0% (2·7 to 3·3; 0·4 to 8·5)
Difference in AIDS-related mortality among people with 
HIV, per 100 person-years 
–0·19 (–0·21 to –0·16; –0·68 to 0·08) –0·17 (–0·19 to –0·15; –0·54 to –0·01) –0·05 (–0·06 to –0·04; –0·28 to 0·11)
Difference in proportion of people with HIV with 
integrase inhibitor resistance, %
+0·8% (0·5 to 1·2; –3·0 to 6·0) –0·4% (–0·5 to –0·3; –2·1 to 0·9) +1·0% (0·7 to 1·2; –2·0 to 4·7)
Difference in proportion of people with HIV with non-
nucleoside reverse transcriptase inhibitor resistance, %
+4·3% (4·1 to 4·5; 1·9 to 7·7) +1·5% (1·3 to 1·6; 0·2 to 3·8) +3·4% (3·3 to 3·6; 1·5 to 6·2)
Difference in HIV incidence in people aged 15–49 years, 
per 100 person-years
–0·04 (–0·05 to –0·03; –0·14 to 0·04) –0·02 (–0·02 to –0·01; –0·10 to 0·06) –0·02 (–0·03 to –0·01; –0·10 to 0·04)
DALYs averted, per year over 10 years 30 400 (27 300 to 33 400; 400 to 91 800) 17 900 (15 700 to 20 000; 
–3200 to 54 800)
16 700 (15 000 to 18 500; 
–2800 to 47 600)
Difference in cost, US$ million per year over 10 years 
(with discounting at 3% per annum)
+42·9 (40·2 to 45·6; 9·0 to 86·5) +5·4 (4·6 to 6·2; –4·9 to 18·7) +42·5 (39·8 to 45·1; 10·1 to 83·9)
Net DALYs averted, per year over 10 years‡ –55 500 (–60 400 to –50 500; 
–135 000 to 7100)
7100 (4700 to 9600); 
–18 000 to 54 800)
–68 200 (–72 900 to –63 500; 
–143 600 to –10 700)
Median cost per DALY averted (90% range) $1638 (390 to 59 524) $404 (dominant to dominated) $2808 (794 to dominated)
Difference in proportion of setting scenarios in which 
injectable CTG–RPV is cost-effective, % (95% CI)
7% (5 to 11) 59% (53 to 64) 2% (0 to 3)
Data are mean (95% CI; 90% range) over 10 years, unless otherwise indicated. Percentage values are absolute (ie, percentage with CTG–RPV – percentage without CTG–RPV). ART=antiretroviral therapy. 
CTG–RPV=cabotegravir–rilpivirine. DALY=disability-adjusted life-year. *Proportion of all initiations of injectable CTG–RPV over the 10 year period for which the most recent viral load was >1000 copies per mL, 
as opposed to the calculation of this proportion for each 3 month period in the 10 years and then taking the mean. This is important for this regimen in all people on ART because there are many initiations of 
injectable CTG–RPV in the first period (when the proportion of people with a most recent viral load of >1000 copies per mL is low), and few subsequent initiations that are all in people initiating ART for the first 
time (hence, viral load is >1000 copies per mL in almost all cases). Because we model true viral load, this is the actual viral load of the person and is not necessarily measured, whereas a clinic would only know a 
person’s viral load if it was measured. †These patients fulfilled the first-line failure or switch criteria. ‡Difference in DALYs + (difference in costs/cost-effectiveness threshold). 
Table 2: Predicted effects of three implementation approaches for the introduction of injectable CTG–RPV
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1000 copies per mL. The introduction of such a regimen 
for this patient group was cost-effective in 59% (95% CI 
53–64) of setting scenarios (table 3). Other policies for 
the introduction of injectable cabotegravir–rilpivirine 
were not cost-effective. These findings are based on our 
assumed cost of $120 for this regimen per person per year. 
We also asked the question of what the maximum cost of 
delivering injectable cabotegravir–rilpivirine would be for 
the introduction of the regimen’s policy for individuals 
with a viral load of more than 1000 copies per mL to be 
cost-effective (ie, for the mean net DALY averted to be ≥0). 
We found such cost to be $131 per person per year.
In further analyses (based on the cost of $120 per person 
per year for injectable cabotegravir–rilpivirine), we 
considered the effects of restricting setting scenarios in 
various ways on the percentage of scenarios in which a 
policy for the regimen in people with a recently measured 
viral load of more than 1000 copies per mL is cost-
effective (table 3). 
Discussion 
We did an exploratory modelling analysis to inform 
potential ways in which the introduction of injectable 
cabotegravir–rilpivirine could have a beneficial effect on 
ART outcomes in patients with HIV in sub-Saharan 
Africa. We found that this regimen could have a substantial 
positive effect if targeted to patients with a viral load 
of more than 1000 copies per mL (despite being on a 
tenofovir disoproxil fumarate–lamivudine–dolutegravir 
regimen), a group for whom adherence to pill taking is 
more likely to be suboptimal. Delivered at a cost of 
below $131 per person per year, injectable cabotegravir–
rilpivirine is potentially cost-effective when used in this 
group. In individuals with a viral load of more than 
1000 copies per mL on a tenofovir disoproxil fumarate–
lamivudine–dolutegravir regimen, there is likely to be 
a considerable risk of integrase inhibitor resistance. Use 
of injectable cabotegravir–rilpivirine instead of the oral 
regimen is not predicted to result in any higher risk. 
Although increasing viral load suppression and reducing 
DALYs, the increased overall costs associated with use of 
injectable cabotegravir–rilpivirine in every patient on ART 
or in those with a viral load of less than 1000 copies per mL 
outweigh the benefits under our assumptions.
We note that the consequences of increased imple-
mentation complexity (including cold chain, syringes, 
coadministration of two separate products, the possible 
need for an oral cabotegravir–rilpivirine dose lead-in to 
rule out serious toxicity, a need to rule out hepatitis B 
before stopping tenofovir, a need to move away from 
injectable cabotegravir–rilpivirine during treatment for 
active tuberculosis, the burden on the patient of monthly 
clinic visits) and time inputs in clinics required with the 
monthly delivery of injectable cabotegravir–rilpivirine 
are not fully known yet. On the basis of our current 
assumptions, the cost associated with these factors would 
need to be considered within the proposed $131 per person 
per year ceiling cost. Injections once every 2 months 
rather than once every month partially reduces some of 
these costs. Additionally, some programmes are not able 
to carry out monitoring of viral load annually as most 
guidelines propose; therefore, this limits the ability to 
implement the policy we modelled.
Subpopulations that might be most susceptible to 
chronic poor adherence to daily oral drugs include 
adolescents and young adults (aged <20 years), and 
mobile workers who might have a particular aversion to 
carrying pills. Individuals who might benefit the most 
might also be those with highest sexual risk behaviour. 
These patients might be the subpopulations in whom 
injectable cabotegravir–rilpivirine is first introduced. We 





Time cabotegravir is at suboptimal concentrations after last injection
3 months in 70% of people, 6 months in 20%, 
1 year in 10%
64% (54–73)
3 months in 33% of people, 6 months in 33%, 
1 year in 33%
53% (44–62)
3 months in 10% of people, 6 months in 20%, 
1 year in 70%
60% (50–69)
Rate of antiretroviral interruption or restart with injectable CTG–RPV 
compared with oral antiretrovirals
Two times higher interruption or two times 
lower restart rate
61% (51–70)
Equal interruption and restart rates 60% (50–69)
Two times lower interruption or two times 
higher restart rate
55% (46–65)
People with lower adherence have a lower risk of sexual transmission 
(ie, fewer condomless partners)
Yes 55% (43–67)
No 60% (53–65)
Percentage of people on ART who have a viral load of <1000 copies 
per mL at baseline
Highest tertile (>92%) 31% (23–40)
Lowest tertile (<87%) 91% (83–95)
Percentage of all people with HIV who have a viral load of <1000 copies 
per mL at baseline*
Highest tertile (>70%) 45% (36–55)
Lowest tertile (<59%) 69% (60–78)
Percentage of people on ART who are on a second-line (protease 
inhibitor-based) regimen at baseline
Highest tertile (>17%) 81% (72–87)
Lowest tertile (<12%) 39% (30–48)
Data are % (95% CI). Baseline refers to 2020. Effects are compared with those of 
not introducing injectable CTG–RPV, according to characteristics of setting 
scenarios and additional changes in assumptions. ART=antiretroviral therapy. 
CTG–RPV=cabotegravir–rilpivirine. *As a measure of overall scope of, and 
engagement with, the ART programme. 
Table 3: Sensitivity analyses showing percentage of setting scenarios in 
which injectable cabotegravir–rilpivirine is cost-effective in people with 
a recently measured viral load of >1000 copies per mL
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according to recent viral load; however, implementation 
studies might consider other direct measures of 
adherence, such as measurement of drug concentrations.
We are mindful that selection of people based on 
increased viral load means that we are likely to select a 
group among whom levels of drug resistance are high, 
and our proposed policy does not include any drug 
resistance testing to detect this given that, until now, 
such testing has not been feasible for programmes. Our 
modelling attempts to take this into account and the 
predicted benefits of the policy are in this context. 
However, such a policy might be viewed as a clinically 
unacceptable approach nevertheless.
Given that a high proportion of people might consider 
injectable cabotegravir–rilpivirine as a convenient 
option, a policy of introducing the regimen only in 
patients with a viral load of more than 1000 copies per 
mL could lead to an incentive of poor adherence to oral 
drugs in individuals who wish to access the injectable 
form; therefore, the approach to implemen tation would 
have to be carefully considered. Because a person with 
close to 100% adherence to oral drugs is likely to have a 
lower risk of resistance with tenofovir disoproxil 
fumarate–lamivudine–dolutegravir than with injectable 
cabotegravir–rilpivirine, if given this information by 
clinical staff, patients could effectively self-select to use 
injectable cabotegravir–rilpivirine if they have concerns 
over their ability to sustain adherence to oral drugs. By 
contrast, those patients who are confident in their ability 
might prefer the reassurance of a predicted very low risk 
of resistance development. In practice, the approach 
tested for provision of injectable cabotegravir–rilpivirine 
might be based on allowing people to make an informed 
choice. It will be important to run such pilot programmes 
to see how use plays out. Our modelling results imply 
that such an approach is unlikely to be cost-effective at 
the drug costs and dosing regimen considered; however, 
uncertainty remains and our modelling should be 
updated when data on actual programme experience are 
available.
We considered whether our conclusions were affected 
by plausible variations between setting scenarios or by 
uncertainty over assumptions. Most notably, we found 
that the policy was less likely to be cost-effective in the 
context of programmes in which the proportion of people 
on ART who had a viral load of less than 1000 copies 
per mL was higher. We also found that the policy was 
more likely to be cost-effective in settings in which there 
was a higher proportion of people on second-line ART. 
This finding probably reflects that, due to the high cost of 
second-line regimens, the benefits provided by injectable 
cabotegravir–rilpivirine in achieving higher levels of viral 
suppression are greater.
A 2020 modelling study considered the minimum 
additional cost of injectable cabotegravir–rilpivirine, 
compared with oral therapy, for this regimen to be 
considered a cost-effective option in adolescents in 
Kenya.17 Using the same $500 per DALY averted cost-
effectiveness threshold as in our study, the authors 
found that an additional annual cost of up to $89 beyond 
the cost of oral treatment could be possible. Although in 
a somewhat different context, this cost is not far from 
the equivalent figure of $53 for our study ($131 – $78 for 
tenofovir disoproxil fumarate–lamivudine–dolutegravir).
Modelling can help to combine the pieces of 
information available, making assumptions as necessary 
and exploring the effect of these assumptions. This 
approach helps to establish what the potential effects of 
policy options and their cost-effectiveness could be, but 
it does not provide empirical data in the way that a 
randomised trial does, and it is important that this 
difference is understood. The main limitation of this 
work is uncertainty over many of the assumptions, 
particularly related to injectable cabotegravir–rilpivirine, 
because it is yet to be introduced into clinical practice.
In conclusion, our modelling suggests that injectable 
cabotegravir–rilpivirine offers potential benefits to 
patients with HIV on ART in low-income settings in 
sub-Saharan Africa; however, its introduction would 
probably need to be carefully targeted if it is to offer a 
cost-effective option, and much uncertainty remains. As 
data accumulate from trials and implementation studies, 
such findings can be incorporated into the model to 
better inform on the full consequences of policy 
alternatives.
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